Protocols
CHIMAGEN-CMG1A46-US01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager CMG1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
MEI-ME-522-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
TENEOBIO-TENEOTWO-TNB486-001 Phase I OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma